What Is the Best Medicine for Rheumatoid Arthritis?

No single medicine is universally “best” for rheumatoid arthritis. The treatment that works depends on how severe the disease is, how your body responds, what other health conditions you have, and sometimes whether you’re planning a pregnancy. That said, the starting point is remarkably consistent: methotrexate has been the go-to first-line drug since the 1980s, and it remains the anchor of most treatment plans today. What gets layered on top of it, or substituted when it fails, is where the real complexity lives.

Why Methotrexate Is Still the Starting Point

Methotrexate holds its position not because it’s the most powerful drug available but because it hits a useful sweet spot of effectiveness, tolerability, safety data, and cost. It works by dampening the overactive immune response that drives joint inflammation, and decades of use have given doctors an unusually deep understanding of its risks and benefits.¹ Most treatment guidelines worldwide recommend starting with methotrexate unless there’s a clear reason not to, such as liver disease, severe kidney problems, or pregnancy plans.

In practice, methotrexate is taken once a week, usually as a pill or a self-administered injection. Side effects can include nausea, mouth sores, and liver enzyme bumps, but most people tolerate it well enough to stay on it long-term. When a Dutch cohort of newly diagnosed patients followed a structured treat-to-target approach starting with methotrexate, about half achieved remission within six months and close to 60 percent within a year.² Those are strong numbers, and they explain why the drug remains step one for nearly everyone.

The Treat-to-Target Philosophy

Modern rheumatology doesn’t just prescribe a drug and hope for the best. The dominant approach is “treat to target,” meaning the explicit goal is clinical remission, or at least very low disease activity, and doctors adjust medications every few months until you get there. An international task force established this framework, recommending remission as the primary treatment target for all patients.³ The idea is simple: if your current regimen isn’t controlling the disease well enough, you escalate rather than accept partial improvement.

This strategy matters more than any single drug choice. Patients managed with a treat-to-target approach consistently show less joint damage over time than those managed with a more passive wait-and-see method. Case series following patients with long-standing disease who received escalating conventional and biologic treatments under this framework demonstrated long-term remission with minimal joint damage progression.⁴ The takeaway is that the system for making drug decisions often matters as much as which drug you start with.

When Methotrexate Isn’t Enough

Roughly a quarter to a third of patients don’t respond adequately to methotrexate alone. The next step is typically adding a biologic or a targeted synthetic drug. Two main options dominate this decision: adding a TNF inhibitor (like etanercept, adalimumab, or infliximab) alongside methotrexate, or trying “triple therapy,” which adds two older conventional drugs (sulfasalazine and hydroxychloroquine) to methotrexate instead.

A large trial published in the New England Journal of Medicine compared these two paths head-to-head. Triple therapy proved noninferior to etanercept plus methotrexate over 48 weeks, with similar improvements in disease activity scores.⁵ That finding surprised many clinicians, because triple therapy costs a fraction of what a biologic costs. However, a network meta-analysis found that for patients with inadequate responses to methotrexate, TNF inhibitor–methotrexate combinations were associated with deeper responses at the highest improvement thresholds.⁶ In other words, the two strategies are broadly comparable for many patients, but TNF inhibitors may offer an edge when the goal is a more complete response.

Why Combination Therapy Usually Beats Monotherapy

One of the clearest findings across RA research is that biologics work better when paired with methotrexate than when used alone. A meta-analysis of randomized trials found that the likelihood of a meaningful clinical response was about a third higher when methotrexate was given alongside a biologic compared to the biologic alone.⁷ Systematic reviews have confirmed this pattern for both TNF and non-TNF biologics: combination therapy with methotrexate improves disease control, remission rates, and physical function compared to using either drug class alone.⁸

There is one notable exception: tocilizumab, a biologic that blocks interleukin-6 rather than TNF, appears to work nearly as well on its own as it does combined with methotrexate. A network meta-analysis found that patient-reported improvements in pain and function with tocilizumab monotherapy were similar to tocilizumab plus methotrexate, while TNF inhibitors clearly performed worse without methotrexate.⁹ For people who truly cannot tolerate methotrexate at any dose, tocilizumab becomes an attractive option for this reason.

JAK Inhibitors and the Safety Question

A newer class of drugs, JAK inhibitors (tofacitinib, baricitinib, upadacitinib, and filgotinib), arrived as oral alternatives to injectable biologics. These are pills taken daily, which many patients prefer. A systematic review and meta-analysis found that all four JAK inhibitors significantly outperformed placebo in reducing disease activity and improving physical function.¹⁰ Head-to-head comparisons suggest the four are broadly similar, though indirect comparisons have found upadacitinib and baricitinib may edge out the others in some response measures, with both showing higher response rates than adalimumab (a TNF inhibitor) in network analyses.¹¹

The catch is safety. A large post-marketing trial (ORAL Surveillance) comparing tofacitinib to TNF inhibitors in older patients with cardiovascular risk factors raised concerns about higher rates of heart attacks, strokes, blood clots, and cancers with JAK inhibition.¹² That trial led the FDA and European regulators to add warnings and restrict JAK inhibitors to patients who haven’t responded to at least one TNF inhibitor.

The picture has gotten more nuanced since then. A systematic review and meta-analysis pooling data from over 40 randomized controlled trials found no statistically significant difference in rates of major cardiovascular events or blood clots between JAK inhibitors and TNF inhibitors.¹³ Another analysis of randomized trial data went further, finding that tofacitinib actually reduced the risk of blood clots compared to placebo.¹⁴ The discrepancy likely reflects the unique design and patient population of the ORAL Surveillance study, which enrolled people already at elevated cardiovascular risk. For younger patients without those risk factors, JAK inhibitors remain a reasonable option, but the regulatory caution persists.

Non-TNF Biologics and the Push Toward Precision

Beyond TNF inhibitors, several biologics target different parts of the immune system. Rituximab depletes B cells, abatacept blocks T-cell co-stimulation, and tocilizumab blocks interleukin-6. When patients fail a TNF inhibitor, switching to one of these is standard practice rather than trying a second TNF inhibitor, though both strategies are used.

An intriguing trial called R4RA tested whether synovial biopsy results could guide the choice between rituximab and tocilizumab in TNF-inadequate responders. In patients whose joint tissue had few B cells, tocilizumab produced significantly higher response rates than rituximab when classified by gene sequencing.¹⁵ This kind of tissue-guided decision-making hints at where the field is heading, but it’s not yet routine. A recent review concluded that reliable biomarkers to predict which patients will respond to which drug are still lacking.¹⁶ For now, drug choices after a first-line failure are still guided largely by clinical judgment, safety profiles, and patient preference rather than molecular testing.

Glucocorticoids as a Bridge, Not a Destination

Steroids like prednisone are sometimes used as “bridging therapy” to tamp down inflammation quickly while slower-acting drugs like methotrexate build up in the system. This practice is common but controversial. A double-blind trial found that short-term high-dose prednisolone bridging showed no benefit over placebo for preventing joint damage at one year.¹⁷ A retrospective study suggested that a single intramuscular steroid injection may work as well as a short course of oral prednisone for bridging, with fewer steroid-related side effects because the total steroid dose is lower.¹⁸ The consensus is that steroids should be used at the lowest effective dose for the shortest possible time, and never as a standalone long-term treatment.

Screening Before You Start Stronger Drugs

Before beginning a biologic or JAK inhibitor, your rheumatologist should screen for latent tuberculosis, hepatitis B, and hepatitis C. These drugs suppress parts of the immune system that keep dormant infections in check, so an undetected infection can reactivate and become dangerous. A study in a country with low TB rates still found substantial numbers of latent TB and positive hepatitis B results among rheumatology patients preparing for intensified treatment.¹⁹ Studies of real-world clinical practice have found that screening rates are far from perfect; one quality-improvement effort raised TB screening from 66 percent to 82 percent, which is better but still means nearly one in five patients slipped through without it.²⁰ If your doctor hasn’t mentioned infection screening before prescribing a biologic, ask about it.

Pregnancy and Rheumatoid Arthritis

Methotrexate is strictly off-limits during pregnancy and must be stopped well in advance of conception. For women who need ongoing RA treatment while pregnant or planning to become pregnant, the options narrow considerably. Certolizumab pegol, a TNF inhibitor with a unique chemical structure that limits its transfer across the placenta, has become the biologic of choice in this setting. Pharmacovigilance data from hundreds of exposed pregnancies have shown no signal for birth defects or increased fetal death compared to the general population.²¹ Larger post-marketing surveillance covering a broad population of patients with chronic inflammatory diseases has reinforced those findings.²² Hydroxychloroquine and sulfasalazine are also generally considered compatible with pregnancy, but the biologic option for women with more active disease is certolizumab.

When RA Affects the Lungs

Rheumatoid arthritis-associated interstitial lung disease is a complication that affects a meaningful minority of RA patients and complicates treatment decisions. Several DMARDs that work well for joints carry possible lung toxicity. Methotrexate, leflunomide, and some biologics have all been linked to rare but serious pulmonary side effects. A review of the evidence found that joint and lung involvement should be evaluated independently of each other when making treatment decisions, because what helps the joints can sometimes hurt the lungs.²³ Patients with this complication often end up on abatacept or rituximab, which have more reassuring pulmonary safety profiles, though the evidence base is still evolving.

Tapering Medications in Remission

Once you’ve been in stable remission for a sustained period, a natural question is whether you can reduce or stop your medications. The evidence here is cautiously encouraging but clear about the risks. A phase 3 trial randomized patients in sustained remission to continue their full dose, taper to half, or taper to zero. At 12 months, about 81 percent of those who stayed on the full dose maintained remission, compared to roughly 59 percent who tapered and 43 percent who stopped entirely.²⁴ A three-year follow-up study of similar tapering strategies found consistent results: 80 percent stayed flare-free on the full dose, compared to 57 percent on half-dose and 38 percent who progressed toward withdrawal.²⁵

The encouraging part is that drug-free remission was achievable for a real subset of patients, and most people who flared after tapering regained remission when their medications were restarted. The practical message: tapering is worth discussing with your rheumatologist if you’ve been in stable remission, but it requires close monitoring and a willingness to resume treatment quickly if symptoms return.

Biosimilars and What They Mean for Access

Biologic drugs are expensive, and biosimilars have reshaped the cost landscape. A biosimilar is not a generic in the traditional sense; it’s a near-identical copy of a biologic that has been tested in rigorous trials to prove it performs the same way. Equivalence studies of adalimumab biosimilars have confirmed therapeutic equivalence to the originator drug at multiple time points.²⁶ Transition studies of infliximab biosimilars have shown that switching mid-treatment from the originator to a biosimilar produces no clinically meaningful changes in efficacy, safety, or immune reactions.²⁷ Long-term data out to 78 weeks have reinforced this, with sustained and comparable efficacy regardless of whether patients started on the biosimilar or were switched to it partway through.²⁸

This matters because biologic underuse is a real worldwide problem driven by cost. In many health systems, access to biologics is restricted by reimbursement criteria that demand patients fail multiple cheaper drugs first, even when earlier biologic use might prevent joint damage.²⁹ Biosimilars, by bringing prices down, have the potential to expand access to effective treatment for people who previously couldn’t afford it or whose insurers wouldn’t cover it.

Exercise, Diet, and Complementary Approaches

Medications are the backbone of RA treatment, but they don’t exist in a vacuum. The American College of Rheumatology published formal guidelines in 2022 recommending exercise, rehabilitation, and certain dietary and integrative interventions alongside DMARDs as part of a comprehensive management approach.³⁰ This wasn’t a vague “exercise is good for you” statement; the panel reviewed the evidence and issued 28 specific recommendations.

A randomized controlled trial found that combining a Mediterranean-style diet with aerobic and strengthening exercise improved pain, inflammation markers, grip strength, and muscle performance in women with RA beyond what exercise alone achieved.³¹ Case reports of comprehensive rehabilitation programs incorporating moderate walking, yoga, and nutritional therapy have documented substantial reductions in painful and swollen joint counts alongside improvements in morning stiffness and overall function.³² None of these approaches replace DMARDs, but they address dimensions of living with RA that drugs alone often leave untouched.

Fatigue, the Symptom Medications Often Miss

If you ask people with RA what bothers them most, fatigue often ranks alongside or above joint pain. A systematic review examining the relationship between fatigue and disease found that even well-treated patients reported high levels of fatigue. Pain was the strongest driver, more so than blood markers of inflammation or composite disease activity scores.³³ This means that getting your inflammation under control is necessary but often not sufficient for feeling well. Fatigue management in RA frequently requires addressing sleep, fitness, mood, and pain separately from the disease activity itself, which is part of why the ACR guidelines emphasize exercise and integrative approaches alongside drug therapy.

The broader point is that “best medicine” in RA isn’t a single pill. It’s a strategy: start methotrexate early, aim for remission, escalate promptly when needed, combine drugs thoughtfully, screen for infections before immune suppression, and pair the whole plan with exercise and lifestyle measures. The landscape of available drugs has expanded enormously over the past few decades, transforming RA from a disease of inevitable disability into one where joint damage can be slowed or stopped for most patients.³⁴ The challenge now is matching the right combination to the right person at the right time.